Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)β’ Click on a phase to view related trials
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy
- Conditions
- Acute myeloid leukemia
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Oncoverity Inc.
- Target Recruit Count
- 26
- Registration Number
- 2024-510991-19-00
- Locations
- πΊπΈ
Banner MD Anderson, Gilbert, Arizona, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈUniversity of California Los Angeles, Los Angeles, California, United States
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04241549
- Locations
- π―π΅
Fukushima Medical University Hospital, Fukushima, Japan
π―π΅Gunmaken Saiseikai Maebashi Hospital, Maebashi, Japan
π―π΅Osaka City General Hospital, Osaka, Japan
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04150887
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΊπΈNorton Cancer Institute, Louisville, Kentucky, United States
πΊπΈBarbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04023526
- Locations
- π¦πΊ
St Vincents Hospital Sydney, Darlinghurst, Australia
π¦πΊSt Vincents Hospital Melbourne, Fitzroy, Australia
π¦πΊThe Alfred Hospital, Melbourne, Australia
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- Drug: AZA
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03030612
- Prev
- 1
- 2
- Next